Disease relevance of ST 900

• When compared with astromicin, amikacin, gentamicin, and sisomicin, dactimicin was similar to astromicin in in vitro activity and was more active than amikacin and gentamicin against the clinical isolates of Serratia marcescens, but less active against Pseudomonas aeruginosa [1].
• Dactimicin inhibited 90% of isolates from the family Enterobacteriaceae at a concentration of less than or equal to 4 micrograms/ml [2].
• The bactericidal activity of dactimicin towards some Gram-positive and Gram-negative bacteria was also evaluated [3].
• Dactimicin was inactivated by the adenyltransferases (AAD) AAD(2") and AAD(9), produced by Pseudomonas aeruginosa, but not by an AAD(4')(4"), produced by a strain of Staphylococcus aureus, nor by an AAD(2") produced by a strain of E. coli [4].
• Dactimicin induced a post-antibiotic effect which ranged from 1 h for Enterobacter cloacae to 2.4 h for Escherichia coli [5].

High impact information on ST 900

• Dactimicin was generally one two-fold dilution step less active or as equally active as gentamicin against enterobacteria and pseudomonas [6].
• The authors considered the antibacterial activity of dactimicin compared with amikacin, gentamicin and the fortimicins against Gram-positive and Gram-negative bacteria [7].
• Pharmacokinetics of dactimicin in rats [8].
• At doses of 200 and 400 mg/kg/day for 4 weeks, no pinna reflex loss was observed, but 2 animals receiving 400 mg dactimicin/kg/day showed unilateral loss of the outer hair cells in the cochlea and very scattered loss of the hair cells in the vestibular organ [9].
• Ototoxic effects of a pseudodisaccharide aminoglycoside antibiotic, dactimicin, on the inner ears of guinea pigs [9].

Chemical compound and disease context of ST 900

• The other three genes, fmrO from the FTM-A producer Micromonospora olivasterospora ATCC 21819, fmrM from the antibiotic SF-2052 producer Micromonospora sp. SF-2098 (ATCC 31580) and fmrD from the dactimicin producer Dactylosporangium matsuzakiense ATCC 31570, conferred resistance to FTM-A, Km and Gm, but not to Nm-B [10].

Anatomical context of ST 900

• At doses of 400 and 500 mg dactimicin/kg/day for 5 weeks, all surviving animals showed no abnormality of the outer hair cells, the inner hair cells and the spiral ganglion cells in the cochlea except for scattered unilateral loss of the outer hair cells and loss of the stria vascularis [9].

Associations of ST 900 with other chemical compounds

• In this study, nephrotoxicity and renal tissue concentrations of gentamicin, amikacin and dactimicin were compared in Wistar rats [11].
• Through comparative studies with astromicin, it was disclosed that the N-formimidoyl group of dactimicin did not increase but decreased the nephrotoxicity, probably by suppressing reabsorption of dactimicin via proximal tubular cells [12].
• In vitro study of dactimicin (ST 900) against methicillin-susceptible and -resistant staphylococci [13].

Analytical, diagnostic and therapeutic context of ST 900

• Dactimicin, a new aminoglycoside probably less toxic than others, also shows in both tests a non-linear correlation between cellular toxicity and concentration or period of contact, but the release of enzyme was significantly reduced during the treatment of the cell cultures with this aminoglycoside [14].
• In the urinalysis of rats at doses of 40 and 80 mg/kg per day for 11 days or 21 days, dactimicin caused little changes in urinary parameters except for nucleated cells and NAG [12].

References